Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.
Press releases published on May 8, 2025

Interpace Biosciences Announces First Quarter 2025 Financial and Business Results
● Q1 Revenue of $11.5 million; a 13% increase year-over-year ● Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ● Q1 Thyroid test volume up 16% year-over-year to record levels ● Q1 Thyroid revenue of $8.0M; up …

The Joint Corp. Reports First Quarter 2025 Financial Results
- Grew revenue from continuing operations 7% compared to Q1 2024 - - Increased system-wide sales 5% for Q1 2025, demonstrating economic resilience - SCOTTSDALE, Ariz., May 08, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, …

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update
- Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Expanded intellectual property portfolio with second patent covering …

Ceribell Reports First Quarter 2025 Financial Results
SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial …

CVRx Reports First Quarter 2025 Financial and Operating Results
MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular …

TOMI Environmental Solutions, Inc. Reports First Quarter 2025 Results
FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its …

SIGA Reports Financial Results for Three Months Ended March 31, 2025
Received $26 Million IV TPOXX Procurement Order from the U.S. Government in March $94 million in TPOXX Orders (to be Delivered to U.S. Strategic National Stockpile) outstanding as of March 31, 2025 Corporate Update Conference Call Today at 4:30 PM ET NEW …

Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales
- New Boston Scientific distribution partnership now underway - - Conference call today at 5:00 p.m. ET / 2:00 p.m. PT - SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting …

BeautyHealth Reports First Quarter 2025 Financial Results
LONG BEACH, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ: SKIN) (“BeautyHealth” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the first quarter ended March 31, 2025 (“Q1 2025”). “ …

Profound Medical Announces First Quarter 2025 Financial Results
TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of …

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025
REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will present data from its …

ICU Medical Announces First Quarter 2025 Results
SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First …

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials …

La Croix-Rouge canadienne insiste sur la nécessité de protéger le personnel humanitaire après un nombre record de décès en 2024
OTTAWA, Ontario, 08 mai 2025 (GLOBE NEWSWIRE) -- À l’occasion de la Journée de la Croix-Rouge et du Croissant-Rouge, la Croix-Rouge canadienne appelle à la protection du personnel humanitaire dans le monde entier. Déjà, cette année, le Mouvement …

NurExone Advances Vision Restoration Strategy with Preclinical Data Presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system …

Nanox to Report First Quarter 2025 Financial Results on May 22, 2025
PETACH TIKVA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended March 31, …

AVITA Medical Reports First Quarter 2025 Financial Results
VALENCIA, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today reported financial results for the first quarter ended March 31, 2025 …

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results
Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of …

Metsera to Present at Bank of America 2025 Global Healthcare Conference
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit …

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to …